These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 750110)

  • 101. The effect of BCNU, CCNU and MeCCNU in the prevention of the development of tumors of the nervous system.
    Pezzotta S; Agradi E; Paoletti P
    Pharmacol Res Commun; 1975 Feb; 07(1):49-53. PubMed ID: 1153462
    [No Abstract]   [Full Text] [Related]  

  • 102. Cellular and molecular mechanisms of the bone marrow sparing effects of the glucose chloroethylnitrosourea chlorozotocin.
    Byrne P; Tew K; Jemionek J; MacVittie T; Erickson L; Schein P
    Blood; 1984 Apr; 63(4):759-67. PubMed ID: 6322885
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Experimental brain tumor chemotherapy: DNA damage in the rat gliosarcoma 9L treated with CCNU.
    Gutin PH; Hilton J; Walker MD
    Clin Neurosurg; 1977; 24():653-64. PubMed ID: 583703
    [No Abstract]   [Full Text] [Related]  

  • 104. In vitro chemosensitivity testing of Fotemustine (S 10036), a new antitumor nitrosourea.
    Fischel JL; Formento P; Etienne MC; Gioanni J; Frenay M; Deloffre P; Bizzari JP; Milano G
    Cancer Chemother Pharmacol; 1990; 25(5):337-41. PubMed ID: 2306793
    [TBL] [Abstract][Full Text] [Related]  

  • 105. The hepatotoxicity of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in rats. Ultrastructural evidence of a delayed microtubular toxicity.
    Ducastelle T; Raguenez-Viotte G; Fouin-Fortunet H; Matysiak M; Hemet J; Fillastre JP
    Cancer Chemother Pharmacol; 1988; 22(2):153-62. PubMed ID: 3409447
    [TBL] [Abstract][Full Text] [Related]  

  • 106. BCNU-sequestration by metallothioneins may contribute to resistance in a medulloblastoma cell line.
    Bacolod MD; Fehdrau R; Johnson SP; Bullock NS; Bigner DD; Colvin M; Friedman HS
    Cancer Chemother Pharmacol; 2009 Mar; 63(4):753-8. PubMed ID: 18633619
    [TBL] [Abstract][Full Text] [Related]  

  • 107. The 9L rat brain tumor: description and application of an animal model.
    Weizsaecker M; Deen DF; Rosenblum ML; Hoshino T; Gutin PH; Barker M
    J Neurol; 1981; 224(3):183-92. PubMed ID: 6162014
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Effects of sodium cyanate in mice bearing B16 melanoma.
    Lea MA; Luke A; Velazquez O; Carpenter L; Martinson CF; Hill HZ; Hill GJ
    Cancer Chemother Pharmacol; 1986; 17(3):231-5. PubMed ID: 3742708
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Pharmacokinetics of 11C-labelled BCNU and SarCNU in gliomas studied by PET.
    Mitsuki S; Diksic M; Conway T; Yamamoto YL; Villemure JG; Feindel W
    J Neurooncol; 1991 Feb; 10(1):47-55. PubMed ID: 1902507
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Chemotherapeutic approaches to brain tumors. Experimental observations with dianhydrogalactitol and dibromodulcitol.
    Levin VA; Wheeler KT
    Cancer Chemother Pharmacol; 1982; 8(1):125-31. PubMed ID: 7094198
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Effect of nitrosoureas on calmodulin activity in vitro and in mouse intestine in vivo.
    Harrison SD; Mann DM; Giles RC
    Cancer Chemother Pharmacol; 1985; 14(2):146-9. PubMed ID: 2982510
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Low apparent risk of CCNU (lomustine)-associated clinical hepatotoxicity in cats.
    Musser ML; Quinn HT; Chretin JD
    J Feline Med Surg; 2012 Dec; 14(12):871-5. PubMed ID: 22772480
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Enhancement of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) toxicity by acetohydroxamic acid analogues of 3-nitropyrazole in vitro.
    Mulcahy RT; Wustrow DJ; Hark RR; Kende AS
    Invest New Drugs; 1987; 5(3):281-7. PubMed ID: 3667163
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Brain, CSF, and tumor pharmacokinetics of alpha-difluoromethylornithine in rats and dogs.
    Levin VA; Csejtey J; Byrd DJ
    Cancer Chemother Pharmacol; 1983; 10(3):196-9. PubMed ID: 6407769
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Development of second malignancies in rats after cure of acute leukemia L 5222 by single doses of 2-chloroethylnitrosoureas.
    Zeller WJ; Schmähl D
    J Cancer Res Clin Oncol; 1979 Sep; 95(1):83-6. PubMed ID: 227910
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Clinical pharmacokinetics of oral CCNU (lomustine).
    Lee FY; Workman P; Roberts JT; Bleehen NM
    Cancer Chemother Pharmacol; 1985; 14(2):125-31. PubMed ID: 3971475
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Animal model for liver dysfunction using lomustine in Wistar rats.
    Tiwari BP; Ramanathan P; Patel RB; Raste AS; Gadre SG; Soman CS; Deodhar KK
    Indian J Gastroenterol; 2000; 19(1):9-11. PubMed ID: 10659479
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Brain tumor chemotherapy using a rat glioma model.
    Tamura M; Mennel HD; Zülch KJ
    J Cancer Res Clin Oncol; 1979 May; 94(1):39-46. PubMed ID: 468898
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Comparison of the transport of chlorozotocin and CCNU in L1210 leukemia and murine bone marrow cells in vitro.
    Lazarus P; Germina JS; Dufour M; Palmer G; Wallace D; Panasci LC
    Cancer Chemother Pharmacol; 1983; 11(3):159-61. PubMed ID: 6227421
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Karyometric, cytophotometric and histoenzymatic studies on neuroglia of rats treated with 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU/lomoustine).
    Szczech J
    Exp Pathol; 1986; 30(4):221-31. PubMed ID: 2949995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.